| Literature DB >> 28346412 |
Jianjun Gao1, John F Ward2, Curtis A Pettaway2, Lewis Z Shi1, Sumit K Subudhi1, Luis M Vence3, Hao Zhao3, Jianfeng Chen1, Hong Chen3, Eleni Efstathiou1, Patricia Troncoso4, James P Allison3,5, Christopher J Logothetis1, Ignacio I Wistuba6, Manuel A Sepulveda7, Jingjing Sun3, Jennifer Wargo8, Jorge Blando3, Padmanee Sharma1,3,5.
Abstract
To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28346412 PMCID： PMC5466900 DOI： 10.1038/nm.4308
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440